Hong Kong children in cramped flats have poorer mental health: survey
Survey results published on Monday also showed that about 40 per cent of children living in subdivided flats said they did not have enough of the spaces at home, a rate that was higher than those in other types of housing.
Hong Kong Metropolitan University and the Society for Community Organisation (SoCO) jointly conducted the poll.
'We hope to look into what impacts the environment in subdivided flats could have on children's mental health, academic results and cognitive development,' said Terence Shum Chun-tat, acting head of the department of social sciences of the university who led the study.
The first phase of the three-year study ran from June 2023 to August 2024 and covered 1,032 children aged 9 to 12.
Around half of them lived in subdivided flats, with the rest in public rental homes, transitional housing, private flats and subsidised housing.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
10 hours ago
- South China Morning Post
Hong Kong study finds lifestyle coaching helps residents lower blood pressure
Around half of Hongkongers with pre-hypertension who joined a personalised healthy lifestyle coaching programme have seen their blood pressure return to normal after six months, a local university has found. The Chinese University of Hong Kong (CUHK) on Tuesday released the findings of a study focused on its Jockey Club We WATCH Healthy Lifestyle Project , which targets middle-aged people to help them prevent chronic diseases. The study, conducted from 2022 to 2025, covered 4,399 participants aged between 35 and 59, who were at high risk of developing chronic diseases. It also found that 51 per cent of participants with borderline or high blood lipids had achieved normal lipid levels, while 48 per cent of those with pre-diabetes had their blood glucose restored to healthy levels. Professor Samuel Wong Yeung-shan, director of the university's School of Public Health and Primary Care, said the findings showed significant improvements in the biometric parameters among participants with higher-risk conditions. 'Instead of saying you are obese, you need to change, we say, what do you want to change and how do the changes affect and facilitate your life goals?' he said, noting that the project eschewed 'traditional, conventional medicine where you have a more didactic and paternalistic approach'.
South China Morning Post
11 hours ago
- South China Morning Post
China's Tianzhou-9 cargo craft launches for Tiangong space station resupply mission
Read more about this: China said it successfully launched its Tianzhou-9 cargo spacecraft on July 15, 2025. The spacecraft is delivering 6.5 tonnes of supplies for the orbiting Tiangong Space Station. The Long March-7 Y10 rocket carrying the spacecraft lifted off at 5.34am from the Wenchang Spacecraft Launch Site in China's southern island province of Hainan, according to the China Manned Space Agency. The Tianzhou-9 separated from the rocket and entered its designated orbit about 10 minutes after blast-off.
South China Morning Post
11 hours ago
- South China Morning Post
‘China's Ozempic' pioneer inks deal with JD Health for online distribution
China's weight loss drugs market could grow to US$5.6 billion by 2035, according to Goldman Sachs Innovent Biologics, the first Chinese company to win regulatory approval to sell a GLP-1 drug for weight loss and diabetes, will leverage JD Health's online distribution network as it seeks to grab a slice of a market that could be worth 40 billion yuan (US$5.6 billion) in a decade. The companies will collaborate on supply chain and sales channel development ahead of Innovent's launch of mazdutide, as well as engage in a consumer education campaign. 'Innovent and JD Health will join hands to popularise knowledge about weight loss and blood sugar control via on and offline channels,' Innovent said in a statement posted on its WeChat account on Tuesday. Late last month, eastern Jiangsu province-based Innovent said it received Chinese regulatory approval for mazdutide, which it claimed was the world's first to mimic the natural hormones of GLP-1 and glucagon, with the latter playing a crucial role in regulating blood glucose levels. GLP-1 drugs mimic the actions of the naturally produced hormone glucagon-like peptide-1, which regulates blood sugar levels, suppresses appetite and slows digestion. A woman injects insulin with an insulin pen to treat her diabetes at home. Photo: Shutterstock Images 'Innovent will make its breakthrough dual-target, liver fat-reducing weight loss therapy available to obese patients as soon as possible, to contribute towards the weight management and healthy China initiatives,' said chairman Michael Yu Dechao, without giving a time frame. Some 34.3 per cent of mainland Chinese adults were estimated to be overweight and 11.2 per cent were obese, according to a 2022 study involving nearly 63,000 participants in 10 provinces. The results were published in 2024 by Public Health, a peer-reviewed journal. Newsletter Every Saturday SCMP Global Impact By submitting, you consent to receiving marketing emails from SCMP. If you don't want these, tick here {{message}} Thanks for signing up for our newsletter! Please check your email to confirm your subscription. Follow us on Facebook to get our latest news. Over 70 per cent of the population would be overweight or obese by 2030, and if the problem was not addressed effectively, it would consume 22 per cent of the nation's total healthcare budget, according to the National Health Commission. Last April, Beijing launched a nationwide weight management campaign as part of its 'healthy China' 2019-2030 action plan, saying obesity had become 'a major public health threat'. China's weight loss drugs market could grow to 40 billion yuan in 2035, according to Chen Ziyi, Goldman Sachs' head of Asia healthcare research. Currently, sales are primarily driven by Denmark-based Novo Nordisk, which reported US$285 million in GLP-1 drug sales for diabetes in China in the first quarter, and US$11 million in sales for weight loss applications. Dozens of Chinese firms are conducting clinical trials on both generic and novel alternatives. Globally, industry estimates for sales of anti-obesity drugs range from US$100 billion to US$150 billion by 2035. JD Health's cold storage facilities in some 300 cities across the mainland could meet Innovent's requirement for GLP-1 drugs to be stored at 2 to 8 degrees Celsius when in transit, Innovent said. Innovent, among the first batch of biotech firms that went public in Hong Kong in 2018, has since launched 16 novel drugs for various types of cancer, as well as for autoimmune, metabolic and eye diseases. Beijing-based JD Health operates one of China's largest online healthcare platforms, with 183.6 million annual active users and an average daily online medical consultation volume of 490,000 last year. Its distribution network spans over 100,000 third-party merchants. Last year, JD Health helped multiple global pharmaceutical firms distribute new drugs in China, including US-based Eli Lilly's GLP-1 diabetes and weight loss drug tirzepatide, a rival to Novo Nordisk's semaglutide. Semaglutide is formulated and marketed as Ozempic for diabetes and Wegovy for weight loss.
